WO1996006572A1 - A device to stop bleeding in living human and animal tissue - Google Patents
A device to stop bleeding in living human and animal tissue Download PDFInfo
- Publication number
- WO1996006572A1 WO1996006572A1 PCT/SE1994/000790 SE9400790W WO9606572A1 WO 1996006572 A1 WO1996006572 A1 WO 1996006572A1 SE 9400790 W SE9400790 W SE 9400790W WO 9606572 A1 WO9606572 A1 WO 9606572A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasma
- tissue
- section
- sections
- channel
- Prior art date
Links
- 230000000740 bleeding effect Effects 0.000 title claims abstract description 52
- 241001465754 Metazoa Species 0.000 title claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- 239000000110 cooling liquid Substances 0.000 claims abstract 2
- 208000002847 Surgical Wound Diseases 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 239000000498 cooling water Substances 0.000 claims description 2
- 229910052735 hafnium Inorganic materials 0.000 claims description 2
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052726 zirconium Inorganic materials 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 abstract description 5
- 238000005345 coagulation Methods 0.000 abstract description 5
- 206010051814 Eschar Diseases 0.000 abstract description 4
- 231100000333 eschar Toxicity 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 description 83
- 208000032843 Hemorrhage Diseases 0.000 description 48
- 231100000319 bleeding Toxicity 0.000 description 48
- 208000034158 bleeding Diseases 0.000 description 48
- 239000007789 gas Substances 0.000 description 42
- 238000000034 method Methods 0.000 description 30
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- 108091006146 Channels Proteins 0.000 description 22
- 230000017074 necrotic cell death Effects 0.000 description 22
- 206010052428 Wound Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 12
- 238000009834 vaporization Methods 0.000 description 12
- 230000008016 vaporization Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000011835 investigation Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000859 sublimation Methods 0.000 description 6
- 230000008022 sublimation Effects 0.000 description 6
- 239000001307 helium Substances 0.000 description 5
- 229910052734 helium Inorganic materials 0.000 description 5
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010891 electric arc Methods 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229910052754 neon Inorganic materials 0.000 description 4
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000412626 Penetes Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
- AANMVENRNJYEMK-UHFFFAOYSA-N 4-propan-2-ylcyclohex-2-en-1-one Chemical compound CC(C)C1CCC(=O)C=C1 AANMVENRNJYEMK-UHFFFAOYSA-N 0.000 description 1
- 244000125300 Argania sideroxylon Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 ar¬ gon Chemical compound 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012809 cooling fluid Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000004157 plasmatron Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/042—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating using additional gas becoming plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/1206—Generators therefor
- A61B2018/1213—Generators therefor creating an arc
Definitions
- the subject invention concerns a device to stop bleeding in live human and animal tissue and to form a crust by means of a plasma jet.
- the invention relates to plasma surgery and more particularly to a new and improved plasma surgical technique of achieving coagulation or a hemostatic effect, i.e. desiccation and coagulation by weak supply of plasma jet power to a layer of tissue and intense supply of jet power to the fluid component of the biological tissue.
- the purpose of the invention resides in plasma dynamic desic ⁇ cation of a surgical site and in the creation in said site of an area of thermal necrosis at a rate highly exceeding the rate of medium or in ⁇ tense bleeding with the aid of direct application of a plasma jet having definite thermo-dynamic characteristics.
- Plasma flow, laser irradiation and electrosurgery are methods used in surgery for clean-cutting purposes, for combined cutting and hemostasis effect as well as for obtaining hemostasis of a surgical wound.
- thermochemical The dominant reactions induced by intense energy application on tissue are thermochemical in nature as a result of the energy absorption by the biological object. The major part of the energy is converted into heat.
- ATC area of thermal changes
- heat is in this case conducted to the boundary of vaporization of the liquid component by means of thermal conductivity. Because during the desiccation of tissue its thermal conductivity is reduced by 4-6 times compared with undesiccated tissue and by 0.62 W/m . °C, the rate of the displacement of the va ⁇ porization boundary with respect to the liquid component diminishes as well, which means that the rate of the ATC creation goes down considerably.
- the use of this method allows the spongy necrosis layer to be obtained only during weak and rather moderate bleeding. This may be understood by the following example.
- the thermal flow at the boundary of vaporization of the liquid component in the tissue must exceed 4.6 x 10 6 W/m 2 .
- the quantity of thermal flow at the boundary of liquid vaporiza ⁇ tion of the liquid component does not exceed 4 x 10 5 W/m 2 .
- energy is supplied to a tissue and allow to penetrate into it.
- a YAG (Nd-YAG) laser beam in the visible and the near-infra ⁇ red region is used as well as electrosurgical application.
- the energy is absorbed into the tissue to a depth of 1.0 mm.
- the amount of thermal energy penetrating into the unit volume of tissue must slightly exceed the energy required to vaporize the blood flow in the tissue and the application must be terminated at the moment of achieving desiccation.
- the energy supply to the tissue is effected by application of high-frequency current to the tissue.
- desic- cation As soon as desic- cation is achieved, its impedence increases considerably, resulting in termination of the application and the achievement of a desiccated layer.
- this method involves feedback during the applica ⁇ tion because the energy supply stops at the moment of tissue surface desiccation, i.e. after the final creation of the spongy necrosis layer. This deminishes the generally harmful effect of the method and provi ⁇ des an opportunity to chose determined regimes with guaranteed power amounts and hence with guaranteed achievement of arresting intensive bleeding.
- the main disadvantages of electrosurgical application on biolo ⁇ gical tissue are the following. In order to stop intensive bleeding it is necessary to increase the amount of energy of the application, which is carried out at the expense of the regime of the microarc generation between the tissue and the surgical instrument.
- the emission of ener- gy in biological tissue involves passing current through a patient, which may limit its usage (for instance in the case of heart diseases). This method does not allow precise incision to be made in tissue in contrast to the characteristics of the laser beam method.
- Fig. 1 is a cross-sectional view through a wound in tissue that has been treated by means of the device in accordance with the in ⁇ vention
- Fig. 2 is a corresponding cross-sectional view through tissue treated by means of an electrosurgical method
- Figs. 3a and b are corresponding sectional views schematically illustrating the inter-active flows to and away from a tissue
- Figs. 4 and 5 shows coordinate systems with curves represen ⁇ ting measured values of thermal energy as a function of plasma jet temperatures
- Fig. 6 is longitudinal sectional view through a plasma nozzle in accordance with one embodiment of the invention wherein an inert gas is used,
- Fig. 6a is a cross-sectional view along line A-A in Fig. 6,
- Figs. 7 and 7a are corresponding sectional views but show a different embodiment of the plasma nozzle wherein the used gas is air and
- Figs. 8 and 8a are corresponding sectional views of a third em ⁇ bodiment of the plasma nozzle using water vapor.
- Fig. 1 is sectional view through a treated wound in a tissue.
- Numeral reference 1 designates a spongy desiccated layer showing locally dead cells (necrosis). This layer 1 is covered by a carbonized layer 2. Owing to heat transfer a compact necrosis layer 3 has formed underneath the spongy desiccated layer 1. The necrosis layer is for ⁇ med between the spongy layer 1 and the unaffected, live tissue 4.
- Fig. 2 shows a wound treated with the aid of electrosurgical technique.
- the spongy layer 1 is characterized by an ex ⁇ ternal, essentially uniform-depth supporting tissue (reticulum) having holes 5 created by means of a light arc.
- the holes are essentially of identical cross-sectional area and are essentially evenly distributed across the eschar surface.
- the tissue intermediate adjacent holes 5 confers pliability to the eschar, preventing cracking.
- generally uniform-depth thermally desiccated layer 3 separates the arc hole re ⁇ ticulum from the unaffected tissue.
- the high porosity of the necrosis layer (as will be shown below it amounts to approximately the percentage of fluid component in the tissue -75-85%) makes it possible to use the essentially novel method of plasma flow to obtain this layer under extensive bleeding condi ⁇ tions.
- the presence of various forms of energy resources is typical of plasma jet.
- the plasma flow energy is concentrated as a form of plas- ma enthalpi, a dynamic component of jet energy and broadband emission of ionized gas.
- the cross-sectional area of the plasma jet and its tem ⁇ perature it becomes possible to control the dynamic pressure of the plasma flow. Consequently, it becomes possible to establish inter- action between the plasma jet and the spongy necrosis layer when the plasma jet penetrates this layer completely or partly.
- the plasma jet is partly cooled while heating the spongy necrosis layer and the remaining part of the jet energy is absorbed at the boundary of the vaporization of the tissue fluid component.
- the filtration of the cooled plasma-generating gas and of the vapour flow takes place through the low pressure area of the plasma jet.
- the maximum cross-section of a plasma jet that realizes penetration of plasma flow in the spongy necrosis layer to a depth of about 0.25 mm equals 3.5 mm in lungs, 3.0 mm in the spleen, 2.5 mm in the liver and 1.5 mm in kidneys.
- Figs. 4 and 5 The results of these investigations are shown in Figs. 4 and 5.
- the black dots correspond to the values of the thermal power and plasma jet temperatures that provide reliable arrest of intensive bleeding.
- Lines I, II, III illustrate the parameters of the plasma jet bo ⁇ undaries beyond which it was not possible to stop bleeding.
- thermo-physical characteristics of the tissue upon phase-structural changes and the formation of ATC - distinction between temperatures of vaporization of the liquid com ⁇ ponent of the tissue and of the sublimation of the charring spongy layer
- Boundary line I defines the condition of gasodynamic penet ⁇ ration of the plasma flow into a porous dessicated tissue layer, to a depth of 0.2-0.25 mm, i.e. exceeding by 3-5 times the a characteristic cross-section of the pores d.
- the position of the boundary I is deter ⁇ mined by tissue species and depends on the cross-sectional area of the plasma jet.
- Boundary line II defines the condition of vaporization of the liquid component of the tissue at a rate exceeding the rate of bleeding.
- the position of boundary II is determined by the extent of cooling of the plasma jet in the bulk of the spongy necrosis layer and is defined by the parameter ⁇ r .
- Boundary line III defines the condition of intensive sublima ⁇ tion of a carbonized spongy layer when the boundary of tissue subli ⁇ mation coincides with the boundary of the fluid component. Besides the limitations mentioned it is necessary to also take into account that the very considerable volume increase of the plasma-generating gas consumption may be the cause of the generation of gaseous em ⁇ bolism. Investigations show that in order to exclude gaseous embo ⁇ lism appearance the value of argan and air consumption must not exceed 2.0 1/min.
- the gas providing the widest range of change of the plasma pa ⁇ rameters and able to arrest heavy bleeding is argon.
- the use of air as the plasma generating gas could also make it possible to stop intensi- ve bleeding but within a much narrower range of plasma parameters compared with argon. It should be noted that in order to generate plasma flows having the above-mentioned parameters some limita- tions of the plasma surgical instrument must be respected.
- surgical microplasmatrons must generate plasma flows having an average mass temperature valid for the given type of gas (argon or air) of a necessarily comparatively high value (argon 7500 - 10 500° K, air 4500 - 5000° K) and that must change only insignificantly during fluctuations of consumption of the plasma-generating gas (between the limits 1.0-2.0 1/min). Furthermore, the above parameters of plas ⁇ ma flow must be achieved with limitation of the value of the discharge current at a level near 30 A, excluding erosion of the electrodes of the microplasmatron .
- the plasma- surgical instrument In order to obtain a guaranteed hemostatic effect in the wound surface during a significant change of the bleeding intensity it is ne ⁇ cessary that the plasma- surgical instrument generates a plasma jet at a stable and comparatively high level of its temperature.
- the jet tem- perature must not change significantly during the regulation of the consumption of the plasma-generating gas.
- This cross-section of the electrical arc results in a high value of the electrical field strength in the channel and the length of the chan- nel that is necessary to heat the argon at the consumption rate of 2.0 1/min is insufficient to provide the electric discharge-distance strength.
- a voltage drop in the plasma of the electric arc increases above 15- 16 V (total value of voltage step input) and in con ⁇ sequence thereof instead of one long arc two sequential arcs appear, burning at a lower voltage and not providing gas heating to a high temperature.
- this channel is designed as electrically isolated sections. Its number must not be less than three.
- the highest electrical field strength is generated by the initial field of the electric arc at the cathode where a cooled gas enters into the arc.
- the length of the channel sections must be increased at a distance from the cathode since the field strength decreases.
- the sections are interconnected via non-electric- ally conductively gaskets.
- the first channel section is connected to the positive pole of a pulse periodic energy accumulator and to a high- voltage spark gap (triggering system of a surgical microplasmatron) .
- the last section is connected to the positive pole of a main power source in the surgical microplasmatron.
- a suitable length of this section is two to three times the diameter of channel d. All chan ⁇ nel sections with the exception of the last one have the same cross- sectional dimensions.
- the last section should, for the purpose of dis- secting tissues in optimal modes of operations, have a channel width of 0.4-0.6 mm. Its design when employed for this purpose does not depend on the kind of plasma-generating gas used.
- the cross- sectional size of the last channel section does, however, depend on both tissue species and type of plasma- generating gas.
- the cross-sectional dimensions of the last channel sections should be 2.5 mm and in the case of kid- neys 1.5 mm.
- a basic embodiment of a plasma surgical unit consisting of an electrically conductive body 6 similar to a pencil with a tip 7 for forming a plasma jet having the required cross- section and connected to a positive pole of a gas power source having a positive potential.
- the body 6 comprises a cylindrical channel to heating the plasma-generating gas and it is formed from channel sec ⁇ tions 8, 9, 10 which are electrically isolated from each other and which are connected to the body 6 through an electrically isolated concentric bush 1 1 having channels 12 for conveyance of cooling fluid to and from the gas heat-ing channel.
- the sections 8, 9, 10 are inter ⁇ connected by means of non-electrically conductive sleeves 22.
- the last section 10 which is designed to form the plasma jet, is connected with the tip 7 and has a channel cross-section df to stop bleedings from large surgical wounds.
- the cross-section depends on the kind of plasma-generating gas and the species of the biological tissue.
- the channel of section 10 is constructed as two co-axial cylindrical holes 17, 18 (see Fig.
- the first section 8 is configured as a hollow cylindrical electrode which is connected with the body 6 via the electrically isolated bush 1 1 and with the cathode 13, 14 via the electrically isolated sealing bush 15.
- the sections are mutually interconnected via electrically in ⁇ sulated gaskets 22.
- the cathode consists of an electrically conductive tube 14 on one end of which the electrode 13 from a high-melting metal is fixed, providing the required level of current for thermal-electronic emission within the working range of discharged currents.
- the opposite end of the tube serves as a connection to the gas supply unit and is connec- ted with the negative poles of the basic energy source and of the trig ⁇ ger system of the microplasmatron.
- the electrically conductive tube 14 is formed with holes 16 for input and uniform distribution of the plasma-generating gas to the discharge chamber of the micro ⁇ plasmatron.
- the electrode of the cathode 13 is made from wolfram or its alloys.
- the electrode of the cathode 13 is made from zirconium or hafnium (Figs. 7, 8).
- the second last and the last sections 9 and 10 are formed at the beginning and the end, respectively, with tangentially positioned channels 19 (see Fig. 8) which are connected to the channel heating the plasma-generating gas and having the volume separated from the cooling water by means of inserts 20 formed with pores positioned in ⁇ side a heat insulated cylindrical sleeve 21.
- the porous inserts 20 cover at least half of the external surface of the second last and the last sections 9 and 10.
- the water-filled cavity is connected to a system regulating the water pressure in order to control the quantity of steam consumption.
- the discharge current provides the required tempera ⁇ ture of the plasma flows and the size of the steam consumption is between 3.0 and 8.0 A.
- the eschar resulting from the use of the device proposed in accordance with the subject invention has a well defined spongy necrosis layer having a thickness of 0.15-0.25 mm, which corresponds to between 3 and 5 characteristic cross- sections of pores therein.
- the porous layer in accordance with the invention has a well defined boundary towards the subjacent tissue, which indicates the highly restricted heat penetration into the tissue and the localisation in this area of the boundary of vaporization of the liquid component of the tissue.
- SNL spongy necrosis layer
- the pore size upon plasma exposure is 1.5 times less that upon laser exposure and the thickness of tissue intermediate the pores is 1.3 times larger. This indicates that the permiability of a spongy des- sicated layer is approximately similar to that of a dessicated tissue obtained by means of methods involving slow heating at a tempera ⁇ ture which only slightly exceeds that of vaporization of the tissue liq ⁇ uid component of the tissue.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plasma & Fusion (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Otolaryngology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Plasma Technology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9301850A SE503334C2 (en) | 1993-06-01 | 1993-06-01 | Device for stopping bleeding and forming a crust by means of a plasma jet |
DK94929701T DK0784452T3 (en) | 1994-08-29 | 1994-08-29 | Apparatus for stopping bleeding in living human and animal tissues |
AU78657/94A AU7865794A (en) | 1993-06-01 | 1994-08-29 | A device to stop bleeding in living human and animal tissue |
EP94929701A EP0784452B1 (en) | 1994-08-29 | 1994-08-29 | A device to stop bleeding in living human and animal tissue |
JP50865196A JP3565561B2 (en) | 1994-08-29 | 1994-08-29 | Device for stopping bleeding in living tissues of humans and animals |
ES94929701T ES2207640T3 (en) | 1994-08-29 | 1994-08-29 | DEVICE TO STOP THE HEMORRAGIES OF THE LIVING FABRICS OF HUMAN BEINGS AND ANIMALS. |
PCT/SE1994/000790 WO1996006572A1 (en) | 1993-06-01 | 1994-08-29 | A device to stop bleeding in living human and animal tissue |
CA002198000A CA2198000C (en) | 1993-06-01 | 1994-08-29 | A device to stop bleeding in living human and animal tissue |
US08/809,203 US5843079A (en) | 1994-08-29 | 1994-08-29 | Device to stop bleeding in living human and animal tissue |
AT94929701T ATE252348T1 (en) | 1994-08-29 | 1994-08-29 | HEMOSTATIC DEVICE FOR LIVING HUMAN AND ANIMAL TISSUE |
DE69433269T DE69433269T2 (en) | 1994-08-29 | 1994-08-29 | Hemostasis device for living human and animal tissues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9301850A SE503334C2 (en) | 1993-06-01 | 1993-06-01 | Device for stopping bleeding and forming a crust by means of a plasma jet |
PCT/SE1994/000790 WO1996006572A1 (en) | 1993-06-01 | 1994-08-29 | A device to stop bleeding in living human and animal tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996006572A1 true WO1996006572A1 (en) | 1996-03-07 |
Family
ID=26661751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1994/000790 WO1996006572A1 (en) | 1993-06-01 | 1994-08-29 | A device to stop bleeding in living human and animal tissue |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU7865794A (en) |
CA (1) | CA2198000C (en) |
SE (1) | SE503334C2 (en) |
WO (1) | WO1996006572A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004030551A1 (en) * | 2002-10-04 | 2004-04-15 | Plasma Surgical Investments Limited | Plasma surgical device |
EP1089668B1 (en) * | 1998-06-24 | 2005-05-25 | Plasma Surgical Investments Limited | Plasma knife |
US7589473B2 (en) | 2007-08-06 | 2009-09-15 | Plasma Surgical Investments, Ltd. | Pulsed plasma device and method for generating pulsed plasma |
JP2010536123A (en) * | 2007-08-06 | 2010-11-25 | プラズマ スルギカル インベストメントス リミテッド | Pulse plasma apparatus and method for generating pulsed plasma |
WO2011091855A1 (en) * | 2010-01-29 | 2011-08-04 | Plasma Surgical Investments Limited | Methods of sealing vessels using plasma |
WO2012005132A1 (en) | 2010-07-07 | 2012-01-12 | 独立行政法人産業技術総合研究所 | Plasma irradiation treatment device |
US9089319B2 (en) | 2010-07-22 | 2015-07-28 | Plasma Surgical Investments Limited | Volumetrically oscillating plasma flows |
US9913358B2 (en) | 2005-07-08 | 2018-03-06 | Plasma Surgical Investments Limited | Plasma-generating device, plasma surgical device and use of a plasma surgical device |
US11882643B2 (en) | 2020-08-28 | 2024-01-23 | Plasma Surgical, Inc. | Systems, methods, and devices for generating predominantly radially expanded plasma flow |
CN117860369A (en) * | 2024-01-19 | 2024-04-12 | 遵义医科大学珠海校区 | Hemostatic manipulator for percutaneous nephroscope |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991764A (en) * | 1973-11-28 | 1976-11-16 | Purdue Research Foundation | Plasma arc scalpel |
US4788408A (en) * | 1987-05-08 | 1988-11-29 | The Perkin-Elmer Corporation | Arc device with adjustable cathode |
US4855563A (en) * | 1986-08-11 | 1989-08-08 | Beresnev Alexei S | Device for plasma-arc cutting of biological tissues |
WO1992019166A1 (en) * | 1991-04-15 | 1992-11-12 | Nauchno-Issledovatelsky Institut Energeticheskogo Mashinostroenia Moskovskogo Gosudarstvennogo Tekhnicheskogo Universiteta Imeni N.E.Baumana | Device for plasma surgical treatment of biological tissues |
-
1993
- 1993-06-01 SE SE9301850A patent/SE503334C2/en unknown
-
1994
- 1994-08-29 AU AU78657/94A patent/AU7865794A/en not_active Abandoned
- 1994-08-29 CA CA002198000A patent/CA2198000C/en not_active Expired - Lifetime
- 1994-08-29 WO PCT/SE1994/000790 patent/WO1996006572A1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991764A (en) * | 1973-11-28 | 1976-11-16 | Purdue Research Foundation | Plasma arc scalpel |
US4855563A (en) * | 1986-08-11 | 1989-08-08 | Beresnev Alexei S | Device for plasma-arc cutting of biological tissues |
US4788408A (en) * | 1987-05-08 | 1988-11-29 | The Perkin-Elmer Corporation | Arc device with adjustable cathode |
WO1992019166A1 (en) * | 1991-04-15 | 1992-11-12 | Nauchno-Issledovatelsky Institut Energeticheskogo Mashinostroenia Moskovskogo Gosudarstvennogo Tekhnicheskogo Universiteta Imeni N.E.Baumana | Device for plasma surgical treatment of biological tissues |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1089668B1 (en) * | 1998-06-24 | 2005-05-25 | Plasma Surgical Investments Limited | Plasma knife |
US7361175B2 (en) | 2002-10-04 | 2008-04-22 | Plasma Surgical Investments Limited | Plasma surgical device |
CN100408000C (en) * | 2002-10-04 | 2008-08-06 | 普拉斯马外科投资有限公司 | Plasma surgical device |
WO2004030551A1 (en) * | 2002-10-04 | 2004-04-15 | Plasma Surgical Investments Limited | Plasma surgical device |
US12075552B2 (en) | 2005-07-08 | 2024-08-27 | Plasma Surgical, Inc. | Plasma-generating device, plasma surgical device and use of a plasma surgical device |
US9913358B2 (en) | 2005-07-08 | 2018-03-06 | Plasma Surgical Investments Limited | Plasma-generating device, plasma surgical device and use of a plasma surgical device |
US10201067B2 (en) | 2005-07-08 | 2019-02-05 | Plasma Surgical Investments Limited | Plasma-generating device, plasma surgical device and use of a plasma surgical device |
US7589473B2 (en) | 2007-08-06 | 2009-09-15 | Plasma Surgical Investments, Ltd. | Pulsed plasma device and method for generating pulsed plasma |
JP2010536123A (en) * | 2007-08-06 | 2010-11-25 | プラズマ スルギカル インベストメントス リミテッド | Pulse plasma apparatus and method for generating pulsed plasma |
WO2011091855A1 (en) * | 2010-01-29 | 2011-08-04 | Plasma Surgical Investments Limited | Methods of sealing vessels using plasma |
WO2012005132A1 (en) | 2010-07-07 | 2012-01-12 | 独立行政法人産業技術総合研究所 | Plasma irradiation treatment device |
US9089319B2 (en) | 2010-07-22 | 2015-07-28 | Plasma Surgical Investments Limited | Volumetrically oscillating plasma flows |
US10492845B2 (en) | 2010-07-22 | 2019-12-03 | Plasma Surgical Investments Limited | Volumetrically oscillating plasma flows |
US10631911B2 (en) | 2010-07-22 | 2020-04-28 | Plasma Surgical Investments Limited | Volumetrically oscillating plasma flows |
US12023081B2 (en) | 2010-07-22 | 2024-07-02 | Plasma Surgical, Inc. | Volumetrically oscillating plasma flows |
US10463418B2 (en) | 2010-07-22 | 2019-11-05 | Plasma Surgical Investments Limited | Volumetrically oscillating plasma flows |
US11882643B2 (en) | 2020-08-28 | 2024-01-23 | Plasma Surgical, Inc. | Systems, methods, and devices for generating predominantly radially expanded plasma flow |
US12058801B2 (en) | 2020-08-28 | 2024-08-06 | Plasma Surgical, Inc. | Systems, methods, and devices for generating predominantly radially expanded plasma flow |
CN117860369A (en) * | 2024-01-19 | 2024-04-12 | 遵义医科大学珠海校区 | Hemostatic manipulator for percutaneous nephroscope |
Also Published As
Publication number | Publication date |
---|---|
SE503334C2 (en) | 1996-05-28 |
CA2198000A1 (en) | 1996-03-07 |
SE9301850D0 (en) | 1993-06-01 |
SE9301850L (en) | 1994-12-02 |
AU7865794A (en) | 1996-03-22 |
CA2198000C (en) | 2006-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5843079A (en) | Device to stop bleeding in living human and animal tissue | |
KR100466866B1 (en) | Electrode for radiofrequency tissue ablation | |
US8308724B2 (en) | Bipolar electrosurgical device with floating-potential electrodes | |
US7354438B2 (en) | Devices for electrosurgery | |
US7238185B2 (en) | Method and apparatus for plasma-mediated thermo-electrical ablation | |
US8057468B2 (en) | Method to generate a plasma stream for performing electrosurgery | |
US6277115B1 (en) | Apparatus and method for treating body tissues | |
US8221404B2 (en) | Electrosurgical ablation apparatus and method | |
US9468487B2 (en) | Medical instrument and method of use | |
US3434476A (en) | Plasma arc scalpel | |
US3991764A (en) | Plasma arc scalpel | |
US20040116918A1 (en) | Electrosurgical device to generate a plasma stream | |
US20090270849A1 (en) | Electrosurgical Device and Method | |
US20040002746A1 (en) | Thermal coagulation using hyperconductive fluids | |
WO1996006572A1 (en) | A device to stop bleeding in living human and animal tissue | |
RU2195226C2 (en) | Method for high-frequency electrosurgical action on biologic tissues | |
CZ35024U1 (en) | Equipment for producing plasma with nitric oxide | |
Brill | Principles and practice of electrosurgery | |
Desinger | Fundamentals of minimally invasive radiofrequency applications in ear, nose and throat medicine | |
Desinger | 39 invasive radiofrequency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2198000 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994929701 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08809203 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994929701 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994929701 Country of ref document: EP |